The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
Clinical trial NCT02679196 · COMPLETED
Trial details
- NCT number
- NCT02679196
- Sponsor
- Karus Therapeutics Limited
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-01
- Primary completion
- 2018-12-24
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.